期刊文献+

多囊脂质体-海藻酸钠微球的理化性质及初步稳定性研究 被引量:1

Physicochemical Property and Stability of MVLs-Alg Microspheres
原文传递
导出
摘要 目的:制备蛋白类药物的多囊脂质体-海藻酸钠(MVLs-Alg)微球,并研究其理化性质和初步的稳定性。方法:以牛血清蛋白(BSA)为模型蛋白药物,采用内部/凝胶化法制备MVLs-Alg微球,然后采用差示热分析MVLs-Alg微球中MVLs与Alg之间的关系,以及研究温度(4、25、40℃)对其包封率和基质中磷脂的过氧化值的影响。结果:制备的微球球型度好,MVLs与Alg之间可能发生了相互吸附,放置90d时,4、25、40℃条件下微球包封率分别为85.36%、63.75%、50.49%,磷脂过氧化值随温度升高不断增大,但与MVLs比较变化不明显。结论:所制备的微球明显提高了脂类的稳定性,可用于蛋白质类药物的输送。 OBJECTIVE: To prepare multivesicular liposomes-sodium polymannuronate microspheres (MVLs-Alg) for protein drugs and to study the physico - chemical property and elementary stability of MVLs - Alg. METHODS: MVLs and Alg were used as matrix and BSA as a model protein drug, MVLs- Alg microspheres were prepared by interior/ gelatin method. The relationship between MVLs and Alg was analyzed by differential thermal analysis and the effect of temperature (4, 25, 40 ℃ ) on entrapment efficiency and peroxide value of phospholipid in base material was investigated. RESULTS: The MVLs-Alg microspheres were spherical. Analyzed by DTA, it was considered that physical adsorption between MVLs and Alg was potentially existed. Storing for 90 days at 4, 25, and 40 ℃ respectively, the encapsulation efficiency of the MVLs- Alg microsphereswere were 85.36%, 63.75%, and 50.49%, respectively. The peroxide value of phospholipid increased increasingly, but not significant as compared with MVLs. CONCLUSIONS: The stability of MVLs- Alg microspheres was heightened compared with that of MVLs and which can be used for the delivery of protein drugs.
出处 《中国药房》 CAS CSCD 北大核心 2008年第28期2203-2205,共3页 China Pharmacy
基金 中国博士后基金资助项目(20070410029) 重庆市教委科学基金资助项目(KJ081401)
关键词 多囊脂质体 微球 蛋白质 性质 Multivesicular liposomes Microspheres Protein Property
  • 相关文献

参考文献5

二级参考文献63

共引文献35

同被引文献27

  • 1徐成业,陈亭亭,陆伟根.大分子乳化剂对复乳稳定性的影响及应用[J].中国医药工业杂志,2011,42(6):460-465. 被引量:2
  • 2陈亭亭,陆伟根.多囊脂质体的应用现状[J].世界临床药物,2007,28(3):170-173. 被引量:1
  • 3Jain SK, Jain RK, Chourasia MK, et al. Design and development of multivesicular liposomal depot delivery system for controlled systemic delivery of acyclovir sodium [J]. AAPSPharmSciTech, 2005, 6 (1) : E35-E41.
  • 4Li H, An JH, Park JS, et al. Multivesicular liposomes for oral delivery of recombinant human epidermal growth factor [J]. Arch Pharm Res, 2005, 28 (8) : 988-994.
  • 5Kim S, Howell SB. Method for treating neurological disorders: US, 5455044 [P]. 1995-10-03.
  • 6Ye Q, Sankaram MB. Method for producing liposomes with increased percent of compound encapsulated: US, 5997899 [P]. 1999-12-07.
  • 7Kim S, Kim T, Murdande S. Sustained-release liposomal anesthetic composition: US, 8182835 [P]. 2012-05-22.
  • 8Brain McAlvin J, Padera RF, Shankarappa SA, et al. Multivesicular liposomal bupivacaine at the sciatic nerve [J]. Biomaterials, 2014, 35 (15): 4557-4564.
  • 9Matos M, Guti6rrez G, Coca J, et al. Preparation of water-in- oil-in-water (Wl/O/W2) double emulsions containing trans- resveratrol [J]. Colloid Surface A, 2014, 442: 69-79.
  • 10Ye Q, Sankaram MB. Method for producing liposomes with increased percent of compound encapsulated: US, 6171613 [P]. 2001-01-09.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部